Literature DB >> 12416580

FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer.

Shinya Oku1, Keiichi Nakagawa, Toshimitsu Momose, Yoshitaka Kumakura, Atsushi Abe, Toshiaki Watanabe, Kuni Ohtomo.   

Abstract

UNLABELLED: In the management of rectal cancer after the combined therapy of the radiation and surgical operation, the evaluation of the prognosis is important. Although fluoro- 18-deoxyglucose positron emission tomography (FDG-PET) is considered as a useful tool for evaluation of therapeutic effect of this cancer as well as the other cancers, however, there are few articles that clearly describe the appropriate procedure of the FDG-PET in order to obtain the best prognostic value. The purpose of the present study is to compare several variations of a semi-quantification method, the Standardized Uptake Values (SUV) and to determine the most appropriate parameter, for the prognostic prediction and to propose the quantitative guideline of the FDG-PET. Especially, the authors focused on the SUV after radiotherapy, which had not been considered as a key quantitative value, as it was rather taken as a mere indicator of the therapeutic (radiotherapeutic) effect, not a direct indicator of the prognosis for the cancer itself.
METHODS: Forty patients with rectal cancer in the lower rectal region underwent two series of FDG-PET study before and after pre-operative radiotherapy. Their SUVs were calculated from FDG-PET data and compared with the results of the long-term follow-up of the patients as well as with histopathological outcomes.
RESULTS: All 40 patients had high FDG uptake before radiotherapy. The mean value of SUV before radiotherapy (SUV1) was 7.6. After radiotherapy, the mean value of SUV (SUV2) decreased to 4.2. There was a significant difference in SUV2 between the groups with and without recurrence (p < 0.05), however, SUVI or SUV ratio (SUV2/SUV1) displayed no significant difference with the incidence of recurrence.
CONCLUSION: SUV2 was considered to be a good prognostic indicator for long-term prognosis of rectal cancer patients. SUV1 nor SUV ratio SUV2/SUV1 did not have the equivalent prognostic usefulness. Subsets of patients with SUV2 greater than 3.2 should be observed closely.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12416580     DOI: 10.1007/bf02990079

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  13 in total

1.  Positron emission tomography as predictor of rectal cancer response during or following neoadjuvant chemoradiation.

Authors:  Shane Hopkins; Marwan Fakih; Gary Y Yang
Journal:  World J Gastrointest Oncol       Date:  2010-05-15

2.  Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas.

Authors:  Matthias H M Schwarzbach; Ulf Hinz; Antonia Dimitrakopoulou-Strauss; Frank Willeke; Servando Cardona; Gunhild Mechtersheimer; Thomas Lehnert; Ludwig G Strauss; Christian Herfarth; Markus W Büchler
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

3.  The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT.

Authors:  Robert Rosenberg; Ken Herrmann; Ralf Gertler; Beat Künzli; Markus Essler; Florian Lordick; Karen Becker; Tibor Schuster; Hans Geinitz; Matthias Maak; Markus Schwaiger; Jörg-Rüdiger Siewert; Bernd Krause
Journal:  Int J Colorectal Dis       Date:  2008-12-03       Impact factor: 2.571

4.  Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment [(18)F]FDG PET/CT scans in locally advanced rectal cancer.

Authors:  Ji-In Bang; Seunggyun Ha; Sung-Bum Kang; Keun-Wook Lee; Hye-Seung Lee; Jae-Sung Kim; Heung-Kwon Oh; Ho-Young Lee; Sang Eun Kim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-04       Impact factor: 9.236

Review 5.  The role of SPET and PET in monitoring tumour response to therapy.

Authors:  Chariklia Giannopoulou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-14       Impact factor: 9.236

6.  Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy.

Authors:  Carlo Capirci; Lucia Rampin; Paola A Erba; Fabrizio Galeotti; Giorgio Crepaldi; Elena Banti; Marcello Gava; Stefano Fanti; Giuliano Mariani; Pier Carlo Muzzio; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-15       Impact factor: 9.236

7.  Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation.

Authors:  Andre Konski; Tianyu Li; Elin Sigurdson; Steven J Cohen; William Small; Stewart Spies; Jian Q Yu; Andrew Wahl; Steven Stryker; Neal J Meropol
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-10       Impact factor: 7.038

8.  Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy.

Authors:  H Shoda; Y Kakugawa; D Saito; T Kozu; T Terauchi; H Daisaki; C Hamashima; Y Muramatsu; N Moriyama; H Saito
Journal:  Br J Cancer       Date:  2007-11-27       Impact factor: 7.640

9.  Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial.

Authors:  S Loi; S Y K Ngan; R J Hicks; B Mukesh; P Mitchell; M Michael; J Zalcberg; T Leong; D Lim-Joon; J Mackay; D Rischin
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

Review 10.  PET/CT imaging in the diagnosis, staging, and follow-up of colorectal cancer.

Authors:  Raghu Vikram; Revathy B Iyer
Journal:  Cancer Imaging       Date:  2008-10-04       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.